159 related articles for article (PubMed ID: 1325216)
21. Breast papillomas with atypical ductal hyperplasia: a clinicopathologic study.
Raju U; Vertes D
Hum Pathol; 1996 Nov; 27(11):1231-8. PubMed ID: 8912836
[TBL] [Abstract][Full Text] [Related]
22. Management of ductal carcinoma in situ with nipple discharge. Intraductal spreading of carcinoma is an unfavorable pathologic factor for breast-conserving surgery.
Ohuchi N; Furuta A; Mori S
Cancer; 1994 Aug; 74(4):1294-302. PubMed ID: 8055451
[TBL] [Abstract][Full Text] [Related]
23. Nuclear chromatin characteristics of breast solid pattern ductal carcinoma in situ.
Frank DH; Davis JR; Alberts DS; Thompson D; Liu Y; Bartels PH
Anal Quant Cytol Histol; 2001 Dec; 23(6):418-26. PubMed ID: 11777277
[TBL] [Abstract][Full Text] [Related]
24. Flow cytometric DNA analysis of excised breast lesions: use of fresh tissue needle aspirates obtained under guidance with mammography of the specimen.
Stomper PC; Stewart CC; Penetrante RB; Nava ME; Tsangaris TN
Radiology; 1992 Nov; 185(2):415-22. PubMed ID: 1329141
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic analysis of breast lesions associated with multiple papillomas.
Ali-Fehmi R; Carolin K; Wallis T; Visscher DW
Hum Pathol; 2003 Mar; 34(3):234-9. PubMed ID: 12673557
[TBL] [Abstract][Full Text] [Related]
26. Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast.
Chuaqui RF; Zhuang Z; Emmert-Buck MR; Liotta LA; Merino MJ
Am J Pathol; 1997 Jan; 150(1):297-303. PubMed ID: 9006344
[TBL] [Abstract][Full Text] [Related]
27. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
28. Nuclear cytometric changes in breast carcinogenesis.
Mommers EC; Poulin N; Sangulin J; Meijer CJ; Baak JP; van Diest PJ
J Pathol; 2001 Jan; 193(1):33-9. PubMed ID: 11169513
[TBL] [Abstract][Full Text] [Related]
29. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
Bofin AM; Lydersen S; Hagmar BM
Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
[TBL] [Abstract][Full Text] [Related]
30. Expression of centrosomal tubulins associated with DNA ploidy in breast premalignant lesions and carcinoma.
Niu Y; Wang S; Liu T; Zhang T; Wei X; Wang Y; Jiang L
Pathol Res Pract; 2013 Apr; 209(4):221-7. PubMed ID: 23523041
[TBL] [Abstract][Full Text] [Related]
31. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis of ductal carcinoma in situ (DCIS) and intraductal papilloma using fluorescence in situ hybridization (FISH) analysis.
Komoike Y; Motomura K; Inaji H; Koyama H
Breast Cancer; 2000; 7(4):332-6. PubMed ID: 11114860
[TBL] [Abstract][Full Text] [Related]
33. Pathology of breast papillary neoplasms: Community hospital experience.
Vdovenko AA
Ann Diagn Pathol; 2020 Dec; 49():151605. PubMed ID: 32920473
[TBL] [Abstract][Full Text] [Related]
34. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
[TBL] [Abstract][Full Text] [Related]
36. DNA ploidy in intraductal breast carcinomas.
Aasmundstad TA; Haugen OA
Eur J Cancer; 1990; 26(9):956-9. PubMed ID: 2177615
[TBL] [Abstract][Full Text] [Related]
37. Feulgen DNA content and mitotic activity in proliferative breast disease. A comparison with ductal carcinoma in situ.
De Potter CR; Praet MM; Slavin RE; Verbeeck P; Roels HJ
Histopathology; 1987 Dec; 11(12):1307-19. PubMed ID: 2831133
[TBL] [Abstract][Full Text] [Related]
38. Immunoreactivity with monoclonal antibody A-80 and nuclear DNA content in benign and malignant human breast disease.
Eriksson E; Schimmelpenning H; Silfverswärd C; Auer G
Hum Pathol; 1992 Dec; 23(12):1366-72. PubMed ID: 1468773
[TBL] [Abstract][Full Text] [Related]
39. Benign, preinvasive and invasive ductal breast lesions. A comparative study with quantitative techniques: morphometry, image- and flow cytometry.
Ruiz A; Almenar S; Callaghan RC; Llombart-Bosch A
Pathol Res Pract; 1999; 195(11):741-6. PubMed ID: 10605693
[TBL] [Abstract][Full Text] [Related]
40. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor.
Xu S; Wei B; Zhang H; Qing M; Bu H
Oncol Rep; 2008 Jun; 19(6):1469-75. PubMed ID: 18497952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
